Tanvex BioPharma Inc (6541) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.058x

Based on the latest financial reports, Tanvex BioPharma Inc (6541) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-309.37 Million ≈ $-9.75 Million USD) by net assets (NT$5.36 Billion ≈ $169.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tanvex BioPharma Inc (6541) liquidity interval to measure how many days the company can operate on defensive assets alone.

Tanvex BioPharma Inc - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tanvex BioPharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tanvex BioPharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tanvex BioPharma Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Chengdu Huasun Group Inc Ltd SHE:000790	-0.142x
Borussia Dortmund GmbH & Co KGaA XETRA:BVB	0.005x
Prince Pipes And Fittings Limited NSE:PRINCEPIPE	0.121x
Balmer Lawrie & Company Limited NSE:BALMLAWRIE	-0.035x
A-LIVING SM.CI.SV. H YC 1 F:1V0	N/A
Telos Corp NASDAQ:TLS	0.083x
Yuen Foong Yu Consumer Prod TW:6790	0.071x
Zhejiang Busen Garments Co Ltd SHE:002569	-0.564x

Annual Cash Flow Conversion Efficiency for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tanvex BioPharma Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Tanvex BioPharma Inc (6541) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$5.69 Billion ≈ $179.39 Million	NT$-1.01 Billion ≈ $-31.68 Million	-0.177x	+86.29%
2024-12-31	NT$893.31 Million ≈ $28.14 Million	NT$-1.15 Billion ≈ $-36.25 Million	-1.288x	+26.24%
2023-12-31	NT$821.11 Million ≈ $25.87 Million	NT$-1.43 Billion ≈ $-45.17 Million	-1.746x	-82.16%
2022-12-31	NT$1.39 Billion ≈ $43.84 Million	NT$-1.33 Billion ≈ $-42.02 Million	-0.959x	-93.15%
2021-12-31	NT$2.79 Billion ≈ $88.05 Million	NT$-1.39 Billion ≈ $-43.70 Million	-0.496x	+27.24%
2020-12-31	NT$2.62 Billion ≈ $82.57 Million	NT$-1.79 Billion ≈ $-56.32 Million	-0.682x	-8.89%
2019-12-31	NT$3.03 Billion ≈ $95.49 Million	NT$-1.90 Billion ≈ $-59.82 Million	-0.626x	-64.42%
2018-12-31	NT$4.21 Billion ≈ $132.79 Million	NT$-1.61 Billion ≈ $-50.59 Million	-0.381x	-17.86%
2017-12-31	NT$3.75 Billion ≈ $118.12 Million	NT$-1.21 Billion ≈ $-38.19 Million	-0.323x	-38.59%
2016-12-31	NT$3.57 Billion ≈ $112.57 Million	NT$-833.43 Million ≈ $-26.26 Million	-0.233x	+50.64%
2015-12-31	NT$1.45 Billion ≈ $45.62 Million	NT$-684.20 Million ≈ $-21.56 Million	-0.473x	+35.83%
2014-12-31	NT$589.64 Million ≈ $18.58 Million	NT$-434.17 Million ≈ $-13.68 Million	-0.736x	-23.91%
2013-12-31	NT$403.64 Million ≈ $12.72 Million	NT$-239.86 Million ≈ $-7.56 Million	-0.594x	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$337.70 Million

NT$10.72 Billion TWD

Market Cap Rank

#14365 Global

#614 in Taiwan

Share Price

NT$40.45

Change (1 day)

-0.12%

52-Week Range

NT$37.40 - NT$65.30

All Time High

NT$287.73